[0017] The scientific and patent literature describes small molecule inhibitors of lysyl oxidase isoenzymes and antibodies of LOX and LOXL2 with therapeutic effects in animal models of fibrosis and cancer metastasis. Some known MAO inhibitors also are reported to inhibit lysyl oxidase isoenzyme (e.g., the MAO-B inhibitor Mofegiline illustrated below). This inhibitor is a member of the haloallylamine family of MAO inhibitors; the halogen in Mofegiline is fluorine. Fluoroallylamine inhibitors are described in US Patent No. 4,454,158. There are issued patents claiming fluoroallylamines and chloroallylamines, for example MDL72274 (illustrated below) as inhibitors of lysyl oxidase (US Patents 4,943,593; 4,965,288; 5,021,456; 5,059,714; 5,182,297; 5,252,608). Many of the compounds claimed in these patents are also reported to be potent MAO-B and SSAO/VAP-1 inhibitors.



Mofegiline MDL72274.

[0018] Additional fluoroallylamine inhibitors are described US Patent 4,699,928. Other examples structurally related to Mofegiline can be found in WO 2007/120528.

[0019] WO 2009/066152 discloses a family of 3-substituted 3-haloallylamines that are inhibitors of SSAO/VAP-1 useful as treatment for a variety of indications, including inflammatory disease. None of these documents specifically disclose the fluoroallylamine compounds of formula (I) according to the present invention.

[0020] Antibodies to LOX and LOXL2 have been disclosed in US 2009/0053224 with methods to diagnostic and therapeutic applications. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state: US 2011/0044907.

Summary

[0021] The present disclosure provides substituted fluoroallylamine compounds that inhibit lysyl oxidase (LOX), lysyl oxidase-like2 (LOXL2) and other lysyl oxidase isoenzymes. Surprisingly, modification of 3-substituted-3-fluoroallylamine structures described previously has led to the discovery of novel compounds that are potent inhibitors of the human LOX and LOXL isoenzymes. Furthermore, certain of these novel compounds also selectively inhibit certain LOX and LOXL isoenzymes with respect to the other enzymes in the amine oxidase family.

[0022] The disclosure provides for a compound of Formula I:



Formula I

or a stereoisomer, pharmaceutically acceptable salt, polymorphic form, solvate, tautomeric form or prodrug thereof; wherein:

a is N or CR^3;

b is N or CR^4;

c is N or CR^5;

d is N or CR^6;

and from 0 to 2 of a, b, c and d are N;

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10} and -NR^9C(O)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, -NO_2, -NR^9R^{10}, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11}, -S(O_2)R^{11}, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11} and -S(O_2)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3.

[0022a] One aspect of the disclosure provides for a compound of Formula I:



Formula I

or a stereoisomer, pharmaceutically acceptable salt, polymorphic form, solvate or tautomeric form thereof; wherein:

a is N or CR^3;

b is N or CR^4;

c is N or CR^5;

d is N or CR^6;

and from 0 to 2 of a, b, c and d are N;

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10} and -NR^9C(O)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, -NO_2, -NR^9R^{10}, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11}, -S(O_2)R^{11}, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11} and -S(O_2)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3.

[0023] The disclosure provides for a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and at least one pharmaceutically acceptable excipient, carrier or diluent.

[0023a] Another aspect of the disclosure provides for a pharmaceutical composition comprising a compound as described herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient, carrier or diluent.

[0024] The disclosure provides for a method of inhibiting the amine oxidase activity of LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition of the disclosure.

[0025] The disclosure provides for a method of treating a condition associated with LOX, LOXL1, LOXL2, LOXL3 and LOXL4 protein, comprising administering to a subject in need thereof a therapeutically effective amount of compound of the disclosure, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition of the disclosure.

[0025a] Another aspect of the disclosure provides for use of a compound as described herein, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating a liver disorder, a kidney disorder, a cardiovascular disease, fibrosis, cancer or angiogenesis.

[0026] The disclosure provides for use of a compound of the disclosure, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the manufacture of a medicament for treating a condition associated with LOX, LOXL1, LOXL2, LOXL3 and LOXL4 protein.

[0027] The disclosure provides for a compound of the disclosure, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in treating a condition associated with LOX, LOXL1, LOXL2, LOXL3 and LOXL4 protein.

[0028] In one example of the methods and uses of the present disclosure the condition is selected from a liver disorder, kidney disorder, cardiovascular disease, fibrosis, cancer and angiogenesis.

[0029] Contemplated herein is combination therapy in which the methods further comprise co-administering additional therapeutic agents that are used for the treatment of liver disorders, kidney disorders, cardiovascular diseases, cancer, fibrosis, angiogenesis and inflammation.

Definitions

[0030] The following are some definitions that may be helpful in understanding the description of the present invention. These are intended as general definitions and should in no way limit the scope of the present invention to those terms alone, but are put forth for a better understanding of the following description.

[0031] Unless the context requires otherwise or specifically states to the contrary, integers, steps, or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements.

[0032] Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements or integers, but not the exclusion of any other step or element or integer or group of elements or integers. Thus, in the context of this specification, the term “comprising” means “including principally, but not necessarily solely”.

[0033] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the

CLAIMS:

1. A compound of Formula I:



Formula I

or a stereoisomer, pharmaceutically acceptable salt, polymorphic form, solvate or tautomeric form thereof; wherein:

a is N or CR^3;

b is N or CR^4;

c is N or CR^5;

d is N or CR^6;

and from 0 to 2 of a, b, c and d are N;

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10} and -NR^9C(O)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, -NO_2, -NR^9R^{10}, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11}, -S(O_2)R^{11}, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11} and -S(O_2)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3.

2. A compound according to claim 1, of Formula Ia:



Formula Ia

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10} and -NR^9C(O)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^3, R^4, R^5 and R^6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, -NO_2, -NR^9R^{10}, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11}, -S(O_2)R^{11}, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11},

-$S(O_2)NR^9R^{10}$, -$NR^9S(O_2)R^{11}$, -$S(O)R^{11}$ and -$S(O_2)R^{11}$; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3.

3. A compound according to claim 1, of Formula Ib:



Formula Ib

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -$C(O)OR^8$, -$C(O)NR^9R^{10}$ and -$NR^9C(O)R^{11}$; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^3, R^4 and R^5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, -NO_2, -NR^9R^{10}, -$C(O)OR^8$, -$C(O)NR^9R^{10}$, -$NR^9C(O)R^{11}$, -$S(O_2)NR^9R^{10}$, -$NR^9S(O_2)R^{11}$, -$S(O)R^{11}$, -$S(O_2)R^{11}$, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, -$C(O)OR^8$, -$C(O)NR^9R^{10}$, -$NR^9C(O)R^{11}$, -$S(O_2)NR^9R^{10}$, -$NR^9S(O_2)R^{11}$, -$S(O)R^{11}$ and -$S(O_2)R^{11}$; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3.

4. A compound according to claim 1, of Formula Ic:



Formula Ic

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -$C(O)OR^8$, -$C(O)NR^9R^{10}$ and -$NR^9C(O)R^{11}$; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^3, R^4 and R^6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, $-NO_2$, $-NR^9R^{10}$, $-C(O)OR^8$, $-C(O)NR^9R^{10}$, $-NR^9C(O)R^{11}$, $-S(O_2)NR^9R^{10}$, $-NR^9S(O_2)R^{11}$, $-S(O)R^{11}$, $-S(O_2)R^{11}$, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, $-CF_3$, $-CH_2CF_3$, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, $-CF_3$, $-CH_2CF_3$, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, $-CF_3$, $-CH_2CF_3$, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, $-CF_3$, $-CH_2CF_3$, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, $-C(O)OR^8$, $-C(O)NR^9R^{10}$, $-NR^9C(O)R^{11}$, $-S(O_2)NR^9R^{10}$, $-NR^9S(O_2)R^{11}$, $-S(O)R^{11}$ and $-S(O_2)R^{11}$; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, $-CF_3$, $-CH_2CF_3$, and -O-CF_3.

5. A compound according to claim 1, of Formula Id:



Formula Id

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10} and -NR^9C(O)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^3, R^5 and R^6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, -NO_2, -NR^9R^{10}, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11}, -S(O_2)R^{11}, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, -$C(O)OR^8$, -$C(O)NR^9R^{10}$, -$NR^9C(O)R^{11}$, -$S(O_2)NR^9R^{10}$, -$NR^9S(O_2)R^{11}$, -$S(O)R^{11}$ and -$S(O_2)R^{11}$; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3.

6. A compound according to claim 1, of Formula Ie:



Formula Ie

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -$C(O)OR^8$, -$C(O)NR^9R^{10}$ and -$NR^9C(O)R^{11}$; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^4, R^5 and R^6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, -NO_2, -NR^9R^{10}, -$C(O)OR^8$, -$C(O)NR^9R^{10}$, -$NR^9C(O)R^{11}$, -$S(O_2)NR^9R^{10}$, -$NR^9S(O_2)R^{11}$, -$S(O)R^{11}$, -$S(O_2)R^{11}$, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight

or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11} and -S(O_2)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3.

7. A compound according to claim 1, of Formula If:



Formula If

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10} and -NR^9C(O)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^3 and R^4 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, -NO_2, -NR^9R^{10}, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11}, -S(O_2)R^{11}, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11} and -S(O_2)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3.

8. A compound according to claim 1, of Formula Ig:



Formula Ig

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10} and -NR^9C(O)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^2 is aryl or heteroaryl; wherein each R^2 is optionally substituted by one or more R^{12};

R^3 and R^5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{1-6}alkyl, -O-C_{3-7}cycloalkyl, -CN, -NO_2, -NR^9R^{10}, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11}, -S(O_2)R^{11}, tetrazole and oxadiazole; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^8 is selected from the group consisting of hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; or

R^9 and R^{10} when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R^{11} is selected from the group consisting of C_{1-6}alkyl and C_{3-7}cycloalkyl; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, - SH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3; and

R^{12} is selected from the group consisting of halogen, C_{1-6}alkyl, -O-C_{1-6}alkyl, -S-C_{1-6}alkyl, C_{3-7}cycloalkyl, -O-C_{3-7}cycloalkyl, -C(O)OR^8, -C(O)NR^9R^{10}, -NR^9C(O)R^{11}, -S(O_2)NR^9R^{10}, -NR^9S(O_2)R^{11}, -S(O)R^{11} and -S(O_2)R^{11}; wherein each C_{1-6}alkyl is a straight or branched chain alkyl; and wherein each C_{1-6}alkyl and C_{3-7}cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, -OH, -C_{1-3}alkyl, -O-C_{1-3}alkyl, -CF_3, -CH_2CF_3, and -O-CF_3.

9. A compound according to any one of claims 1 to 8, wherein R^2 is selected from the group consisting of phenyl , 1,3-benzodioxolyl , 2-pyridinyl , 3-pyridinyl , 4-pyridinyl  and 5-pyrimidinyl ; wherein each R^2 is optionally substituted by one or more R^{12}.

10. A compound according to any one of claims 1 to 9, wherein R^1 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, 1-hydroxyethyl, 2-hydroxyisopropyl, chloro and -C(O)N(CH_3)$_2$.

11. A compound according to claim 1, selected from the group consisting of:

1		(*Z*)-3-fluoro-4-(3-(4-fluorophenyl)-1*H*-indol-1-yl)but-2-en-1-amine
2		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-1*H*-indol-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
3		(*Z*)-4-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-1*H*-indol-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
4		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-1*H*-pyrrolo[2,3-b]pyridin-3-yl)-*N*,*N*-dimethylbenzenesulfonamide

5		(*Z*)-methyl 1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-2-methyl-1*H*-indole-5-carboxylate
6		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-*N*,*N*,2-trimethyl-1*H*-indole-5-carboxamide
7		(*Z*)-methyl 1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-2-methyl-1*H*-indole-6-carboxylate
8		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-2-methyl-1*H*-indole-5-carboxylic acid

9		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-2-methyl-1*H*-indole-6-carboxylic acid
10		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-*N*,*N*,2-trimethyl-1*H*-indole-6-carboxamide
11		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-2-methyl-1*H*-indole-6-carboxamide
12		(*Z*)-ethyl 1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-2-methyl-1*H*-indole-5-carboxylate

13		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)-2-methylphenyl)-2-methyl-1*H*-indole-5-carboxylic acid
14		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-3-(3-(methylsulfonyl)phenyl)-1*H*-indole-5-carboxylic acid
15		(*Z*)-ethyl 1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(dimethylcarbamoyl)phenyl)-2-methyl-1*H*-indole-5-carboxylate
16		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(dimethylcarbamoyl)phenyl)-2-methyl-1*H*-indole-5-carboxylic acid

17		(*Z*)-ethyl 1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-3-(3-(methylsulfonyl)phenyl)-1*H*-indole-5-carboxylate
18		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-3-(3-(N-methylsulfamoyl)phenyl)-1*H*-indole-5-carboxylic acid
19		(*Z*)-ethyl 1-(4-amino-2-fluorobut-2-en-1-yl)-3-(5-(*N*,*N*-dimethylsulfamoyl)-2-methylphenyl)-2-methyl-1*H*-indole-5-carboxylate
20		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(5-(*N*,*N*-dimethylsulfamoyl)-2-methylphenyl)-2-methyl-1*H*-indole-5-carboxylic acid

21		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-6-fluoro-2-methyl-1*H*-indole-5-carboxylic acid
22		(*Z*)-ethyl 1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-6-fluoro-2-methyl-1*H*-indole-5-carboxylate
23		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(4-fluorophenyl)-2-methyl-1*H*-indole-5-carboxylic acid
24		ethyl (*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(4-fluorophenyl)-2-methyl-1*H*-indole-5-carboxylate

25		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
26		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-1*H*-pyrrolo[3,2-c]pyridin-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
27		ethyl (*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-chlorophenyl)-2-methyl-1*H*-indole-5-carboxylate
28		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-chlorophenyl)-2-methyl-1*H*-indole-5-carboxylic acid
29		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-5-(2*H*-tetrazol-5-yl)-1*H*-indol-3-yl)-*N*,*N*-dimethylbenzenesulfonamide

30		ethyl (*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(tert-butyl)phenyl)-2-methyl-1*H*-indole-5-carboxylate
31		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(tert-butyl)phenyl)-2-methyl-1*H*-indole-5-carboxylic acid
32		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-1*H*-pyrrolo[2,3-c]pyridin-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
33		ethyl (*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-(*N*,*N*-dimethylsulfamoyl)-2-methyl-1*H*-indol-3-yl)benzoate
34		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-(*N*,*N*-dimethylsulfamoyl)-2-methyl-1*H*-indol-3-yl)benzoic acid

35		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-N-isopropyl-2-methyl-1*H*-indole-5-carboxamide
36		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-*N*-isopropyl-*N*,2-dimethyl-1*H*-indole-5-carboxamide
37		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-hydroxy-2-methyl-1*H*-indol-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
38		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-3-(3-(*N*-methylmethylsulfonamido)phenyl)-1*H*-indole-5-carboxylic acid
39		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-*N*,*N*,2-trimethyl-3-(3-(*N*-methylmethylsulfonamido)phenyl)-1*H*-indole-5-carboxamide

40		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(5-(*N*,*N*-dimethylsulfamoyl)pyridin-3-yl)-2-methyl-1*H*-indole-5-carboxylic acid
41		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(5-(*N*,*N*-dimethylsulfamoyl)pyridin-3-yl)-*N*,*N*,2-trimethyl-1*H*-indole-5-carboxamide
42		(*Z*)-ethyl 1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-2-methyl-1*H*-pyrrolo[3,2-b]pyridine-5-carboxylate
43		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-2-methyl-1*H*-pyrrolo[3,2-b]pyridine-5-carboxylic acid

44		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-*N*,*N*,2-trimethyl-1*H*-pyrrolo[3,2-b]pyridine-5-carboxamide
45		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-*N*-isopropyl-2-methyl-1*H*-pyrrolo[3,2-b]pyridine-5-carboxamide
46		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-N,2-dimethyl-1*H*-pyrrolo[3,2-b]pyridine-5-carboxamide
47		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N*,*N*-dimethylsulfamoyl)phenyl)-*N*,*N*,2-trimethyl-1*H*-indole-7-carboxamide

48		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N,N*-dimethylsulfamoyl)phenyl)-2-methyl-1*H*-indole-7-carboxylic acid
49		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-methoxy-2-methyl-1*H*-indol-3-yl)-*N,N*-dimethylbenzenesulfonamide
50		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-*N,N*,2-trimethyl-3-(3-(methylsulfonyl)phenyl)-1*H*-indole-5-carboxamide
51		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-cyano-2-methyl-1*H*-indol-3-yl)-*N,N*-dimethylbenzenesulfonamide

52		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N,N*-dimethylsulfamoyl)phenyl)-*N,N*,2-trimethyl-1*H*-indole-5-carboxamide
53		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N,N*-dimethylsulfamoyl)phenyl)-*N,N*,2-trimethyl-1*H*-pyrrolo[3,2-b]pyridine-5-carboxamide
54		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-*N,N*,2-trimethyl-3-(3-sulfamoylphenyl)-1*H*-indole-5-carboxamide
55		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-5-(1,2,4-oxadiazol-3-yl)-1*H*-indol-3-yl)-*N,N*-dimethylbenzenesulfonamide
56		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-*N,N*,2-trimethyl-3-(3-(trifluoromethyl)phenyl)-1*H*-indole-5-carboxamide

57		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-*N,N*,2-trimethyl-3-(3-((trifluoromethyl)sulfonyl)phenyl)-1*H*-indole-5-carboxamide
58		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(*N,N*-dimethylsulfamoyl)phenyl)-*N,N*,2-trimethyl-1*H*-indole-5-sulfonamide
59		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-(difluoromethyl)-2-methyl-1*H*-indol-3-yl)-*N,N*-dimethylbenzene-sulfonamide
60		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-hydroxy-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N,N*-dimethylbenzene-sulfonamide

61		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-methoxy-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N*,*N*-dimethylbenzene-sulfonamide
62		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-chloro-2-methyl-1*H*-indol-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
63		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-1*H*-indol-3-yl)-*N*,*N*-dimethylpyridine-3-sulfonamide
64		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-chloro-2-methyl-1*H*-indol-3-yl)-*N*,*N*-dimethylpyridine-3-sulfonamide

65		(*Z*)-4-(5-chloro-2-methyl-3-(5-(methylsulfonyl)pyridin-3-yl)-1*H*-indol-1-yl)-3-fluorobut-2-en-1-amine
66		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-chloro-1*H*-indol-3-yl)-*N*,*N*-dimethylpyridine-3-sulfonamide
67		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-6-chloro-2-methyl-1*H*-indol-3-yl)-*N*,*N*-dimethylpyridine-3-sulfonamide
68		(*Z*)-3-fluoro-4-(5-methoxy-2-methyl-3-(3-(methylthio)phenyl)-1*H*-pyrrolo[3,2-b]pyridin-1-yl)but-2-en-1-amine
69		(*Z*)-3-fluoro-4-(5-methoxy-2-methyl-3-(3-(methylsulfonyl)phenyl)-1*H*-pyrrolo[3,2-b]pyridin-1-yl)but-2-en-1-amine

70		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-chloro-2-methyl-1*H*-indol-3-yl)-*N*-methylpyridine-3-sulfonamide
71		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-fluoro-2-methyl-1*H*-indol-3-yl)-*N,N*-dimethylpyridine-3-sulfonamide
72		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-6-chloro-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N,N*-dimethylpyridine-3-sulfonamide
73		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-chloro-2-methyl-1*H*-pyrrolo[2,3-b]pyridin-3-yl)-*N,N*-dimethylpyridine-3-sulfonamide

74		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-7-chloro-2-methyl-1*H*-indol-3-yl)-*N,N*-dimethylpyridine-3-sulfonamide
75		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-4-chloro-2-methyl-1*H*-indol-3-yl)-*N,N*-dimethylpyridine-3-sulfonamide
76		(*Z*)-4-(5-chloro-2-methyl-3-(pyridin-4-yl)-1*H*-indol-1-yl)-3-fluorobut-2-en-1-amine
77		(*Z*)-4-(5-chloro-2-methyl-3-(pyridin-3-yl)-1*H*-indol-1-yl)-3-fluorobut-2-en-1-amine
78		(*Z*)-6-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-chloro-2-methyl-1*H*-indol-3-yl)-*N,N*-dimethylpyridine-2-sulfonamide

79		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-cyclopropyl-2-methyl-1*H*-indol-3-yl)-*N*,*N*-dimethylpyridine-3-sulfonamide
80		(*Z*)-4-(5-chloro-2-methyl-3-(pyrimidin-5-yl)-1*H*-indol-1-yl)-3-fluorobut-2-en-1-amine
81		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-*N*,*N*,2-trimethyl-3-(pyridin-4-yl)-1*H*-indole-5-sulfonamide
82		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-chloro-7-fluoro-2-methyl-1*H*-indol-3-yl)-*N*,*N*,4-trimethylbenzenesulfonamide
83		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-chloro-2-methyl-1*H*-indol-3-yl)pyridine-3-sulfonamide

84		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-3-(pyridin-4-yl)-1*H*-indole-5-sulfonamide
85		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-5-(trifluoromethoxy)-1*H*-indol-3-yl)-*N,N*-dimethylpyridine-3-sulfonamide
86		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-*N,N*,2-trimethyl-3-phenyl-1*H*-indole-5-sulfonamide
87		(*Z*)-3-fluoro-4-(2-methyl-5-(methylsulfonyl)-3-phenyl-1*H*-indol-1-yl)but-2-en-1-amine
88		(*Z*)-3-fluoro-4-(2-methyl-5-(methylsulfonyl)-3-(pyridin-4-yl)-1*H*-indol-1-yl)but-2-en-1-amine

89		(*Z*)-4-(3-(2,6-dimethylpyridin-4-yl)-2-methyl-5-(methylsulfonyl)-1*H*-indol-1-yl)-3-fluorobut-2-en-1-amine
90		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(2,6-dimethylpyridin-4-yl)-*N*,*N*,2-trimethyl-1*H*-indole-5-carboxamide
91		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-*N*-(tert-butyl)-2-methyl-3-(pyridin-4-yl)-1*H*-indole-5-carboxamide
92		(*Z*)-4-(3-(benzo[d][1,3]dioxol-5-yl)-2-methyl-5-(methylsulfonyl)-1*H*-indol-1-yl)-3-fluorobut-2-en-1-amine

93		(*Z*)-3-fluoro-4-(3-(4-fluorophenyl)-2-methyl-5-(methylsulfonyl)-1*H*-indol-1-yl)but-2-en-1-amine
94		(*Z*)-3-fluoro-4-(2-methyl-3-(2-methylpyridin-4-yl)-5-(methylsulfonyl)-1*H*-indol-1-yl)but-2-en-1-amine
95		(*Z*)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(4-fluorophenyl)-2-methyl-1*H*-indole-5-sulfonamide
96		(*Z*)-5-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-chloro-1*H*-indol-3-yl)-*N*,*N*-dimethylpyridine-3-sulfonamide

97		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-5-(methylsulfonyl)-1*H*-indol-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
98		(*Z*)-3-fluoro-4-(3-(2-methoxypyridin-4-yl)-2-methyl-5-(methylsulfonyl)-1*H*-indol-1-yl)but-2-en-1-amine
99		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-chloro-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
100		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-chloro-5-(methylsulfonyl)-1*H*-indol-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
101		(*Z*)-4-(3-(2,6-dimethylpyridin-4-yl)-2-methyl-5-nitro-1*H*-indol-1-yl)-3-fluorobut-2-en-1-amine

102		(*Z*)-*N*-(1-(4-amino-2-fluorobut-2-en-1-yl)-3-(2,6-dimethylpyridin-4-yl)-2-methyl-1*H*-indol-5-yl)methanesulfonamide
103		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-(methoxymethyl)-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
104		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-5-(methylsulfonamido)-1*H*-indol-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
105		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-(dimethylamino)-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N*,*N*-dimethylbenzenesulfonamide
106		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-(isopropylsulfonyl)-2-methyl-1*H*-indol-3-yl)-*N*,*N*-dimethylbenzenesulfonamide

107		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2,5-dimethyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N,N*-dimethylbenzenesulfonamide
108		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-6-fluoro-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N,N*-dimethylbenzenesulfonamide
109		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-fluoro-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N,N*-dimethylbenzenesulfonamide
110		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-5-(trifluoromethyl)-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N,N*-dimethylbenzenesulfonamide

111		(*Z*)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)-5-(1,1-difluoroethyl)-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-3-yl)-*N,N*-dimethylbenzenesulfonamide
112		(*Z*)-4-(2,5-dimethyl-3-(3-(methylsulfonyl)phenyl)-1*H*-pyrrolo[3,2-b]pyridin-1-yl)-3-fluorobut-2-en-1-amine
113		(*Z*)-4-(3-(3-(ethylsulfonyl)phenyl)-2-isopropyl-5-methyl-1*H*-pyrrolo[3,2-b]pyridin-1-yl)-3-fluorobut-2-en-1-amine
114		(*Z*)-4-(3-(3-(ethylsulfonyl)phenyl)-2,5-dimethyl-1*H*-pyrrolo[3,2-b]pyridin-1-yl)-3-fluorobut-2-en-1-amine

115		(*Z*)-3-fluoro-4-(5-(fluoromethyl)-2-methyl-3-(3-(methylsulfonyl)phenyl)-1*H*-pyrrolo[3,2-b]pyridin-1-yl)but-2-en-1-amine
116		(*Z*)-2-(1-(4-amino-2-fluorobut-2-en-1-yl)-2-methyl-3-(3-(methylsulfonyl)phenyl)-1*H*-pyrrolo[3,2-b]pyridin-5-yl)propan-2-ol
117		(*Z*)-2-(1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(isopropylsulfonyl)phenyl)-2-methyl-1*H*-pyrrolo[3,2-b]pyridin-5-yl)propan-2-ol

or a pharmaceutically acceptable salt or solvate thereof.

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient, carrier or diluent.

13. Use of a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating a liver disorder, a kidney disorder, a cardiovascular disease, fibrosis, cancer or angiogenesis.

14. The use of claim 13, wherein the liver disorder is selected from the group consisting of biliary atresia, cholestatic liver disease, chronic liver disease, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), fatty liver disease associated with disorders such as hepatitis or metabolic syndrome; hepatitis C infection, alcoholic liver

disease, primary biliary cirrhosis (PBC), primary schlerosing cholangitis (PSC), liver damage due to progressive fibrosis, liver fibrosis and liver cirrhosis.

15. The use of claim 13, wherein the kidney disorder is selected from the group consisting of kidney fibrosis, renal fibrosis, acute kidney injury, chronic kidney disease, diabetic nephropathy, glomerulosclerosis, vesicoureteral reflux, tubulointerstitial renal fibrosis and glomerulonephritis.

16. The use of claim 13, wherein the cardiovascular disease is selected from the group consisting of atherosclerosis, arteriosclerosis, hypercholesteremia, and hyperlipidemia.

17. The use of claim 13, wherein the fibrosis is selected from the group consisting of liver fibrosis, lung fibrosis, kidney fibrosis, cardiac fibrosis, cystic fibrosis, idiopathic pulmonary fibrosis, radiation-induced fibrosis, ocular fibrosis, Peyronie’s disease and scleroderma or is associated with respiratory disease, abnormal wound healing and repair, post-surgical operations, cardiac arrest and all conditions where excess or aberrant deposition of fibrous material is associated with disease, including Crohn’s disease and inflammatory bowel disease.

18. The use of claim 13, wherein the cancer is selected from the group consisting of lung cancer; breast cancer; colorectal cancer; anal cancer; pancreatic cancer; prostate cancer; ovarian carcinoma; liver and bile duct carcinoma; esophageal carcinoma; non-Hodgkin's lymphoma; bladder carcinoma; carcinoma of the uterus; glioma, glioblastoma, medullablastoma, and other tumors of the brain; myelofibrosis, kidney cancer; cancer of the head and neck; cancer of the stomach; multiple myeloma; testicular cancer; germ cell tumor; neuroendocrine tumor; cervical cancer; oral cancer, carcinoids of the gastrointestinal tract, breast, and other organs; signet ring cell carcinoma; mesenchymal tumors including sarcomas, fibrosarcomas, haemangioma, angiomatosis, haemangiopericytoma, pseudoangiomatous stromal hyperplasia, myofibroblastoma, fibromatosis, inflammatory myofibroblastic tumour, lipoma, angiolipoma, granular cell tumour, neurofibroma, schwannoma, angiosarcoma, liposarcoma, rhabdomyosarcoma, osteosarcoma, leiomyoma or a leiomysarcoma.

19. The use according to any one of claims 13 to 18 further comprising a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of an anti-cancer agent, anti-inflammatory agent, anti-hypertensive agent, an anti-fibrotic agent, an anti-angiogenic agent and an immunosuppressive agent.